Hayes to offer public webinar to help parents of children with ADHD understand the scientific evidence behind a range of ADHD treatments
Lansdale, PA (PRWEB) November 2, 2009 -- www.hayesinc.com [Hayes, Inc., the nation’s leading health technology research and consulting company, today announced that it is offering a consumer-oriented webinar that will unlock the scientific evidence behind various treatments for attention-deficit/hyperactivity disorder (ADHD). In the webinar, Hayes analysts will provide a clear perspective on the benefits, limitations, and potential side effects of a range of ADHD treatments, including pharmaceutical and behavioral approaches.
Hayes CARE professionals will present the webinar. The Hayes CARE program is an innovative workplace benefit for employees and their families. The information provided by Hayes CARE helps employees to understand treatment options, maintain or regain control over their own healthcare decisions, and cope with disruptive health events.
ADHD impacts 4 to 5 million American children, and its treatment is controversial. During the webinar, Elisabeth Houtsmuller (Ph.D.) will explore the clinical evidence behind ADHD treatments for children and cover the benefits and limitations of each, taking into consideration the severity of the symptoms.
In commenting on the webinar, Dr. Houtsmuller said, “Parents of children with ADHD are often overwhelmed by differing opinions about the effectiveness of the various treatments. It is difficult to find unbiased information about treatments, and the Internet is cluttered with conflicting data, some of which has been provided by drug companies with products to sell. At the same time, ADHD is a “lightning rod” issue, and opinions abound from relatives, friends, and neighbors, adding to the confusion.”
“In our webinar, we will provide an unbiased view of ADHD treatments, including prescription drugs such as Adderall® and Strattera®, behavioral therapies, neurofeedback, and over-the-counter treatments such as St. John’s wort and Ginkgo biloba. Our hope is that parents will have the opportunity to learn about treatment options in a forum that is free from the influence of any drug manufacturers, special interest groups, or other marketing biases.”
The one-hour interactive webinar will be offered on November 12, 2009 at 12:00 PM Eastern time and again at 9:00 PM Eastern time. Participants will be able to ask questions through the web-based software. Participants will also receive easy-to-use take-home guides that summarize the information discussed during the program. The registration fee of $19.95 includes all materials.
Dr. Houtsmuller continued, “It is important for parents to be involved in decisions about how to treat their children with ADHD. There are so many options, and most parents don’t have access to the scientific literature. At the same time, finding and calibrating the right treatment for children with ADHD can create family stress. We hope that by offering this webinar we can provide parents with an unbiased and broad perspective to make these challenging and stressful decisions.”
About Hayes, Inc.:
Hayes, Inc. is an independent health technology research and consulting company dedicated to promoting better health outcomes through the use of evidence. Hayes performs unbiased, evidence-based health technology assessments of the safety and efficacy of new, emerging, and controversial health technologies, and evaluates the impact of these technologies on healthcare quality, utilization, and cost. Hayes' worldwide clients include hospitals, healthcare systems, government agencies, employers, and managed care organizations. http://www.hayesinc.com.
Read the full story at http://www.prweb.com/releases/2009/11/prweb3147594.htm.
Copyright©2009 Vocus, Inc.
All rights reserved